WHO Antenatal Care Guideline Implementation Guide
0.3.0 - CI Build International flag

WHO Antenatal Care Guideline Implementation Guide, published by World Health Organization (WHO). This guide is not an authorized publication; it is the continuous build for version 0.3.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/costateixeira/smart-anc/ and changes regularly. See the Directory of published versions

PlanDefinition: ANC.DT.10 Hepatitis C testing

Official URL: http://smart.who.int/anc/PlanDefinition/ANCDT10 Version: 0.3.0
Active as of 2025-06-24 Computable Name: ANCDT10
Other Identifiers: ANC.DT.10 (use: official, )

Usage:Workflow Task: Conduct laboratory tests and imaging

Depending on the population prevalence, and woman's medical history, conduct hepatitis C testing

Id: ANCDT10
Url: ANC.DT.10 Hepatitis C testing
Version: 0.3.0
Official

ANC.DT.10

Title: ANC.DT.10 Hepatitis C testing
Type:

system: http://terminology.hl7.org/CodeSystem/plan-definition-type

code: eca-rule

Date: 2025-06-24 13:58:48-0600
Publisher: World Health Organization (WHO)
Description:

Depending on the population prevalence, and woman's medical history, conduct hepatitis C testing
Use Context:
code value
task
Jurisdiction: 001
Libraries:
ANC.DT.10 Hepatitis C testing
Actions:
ANC.DT.10 Hepatitis C testing:
When: Named Event: ANC.B9. Conduct laboratory tests and imaging
Then:
In settings where the proportion of HCV antibody seroprevalence in the general population is 2% or higher, then a hepatitis C test is required. Anti-HCV laboratory-based immunoassay is the preferred method for testing for Hep C infection in pregnancy; if immunoassay is not available, anti-HCV rapid diagnostic test (RDT) is recommended over dried blood spot (DBS) anti-HCV testing.
If: Applicability: "Population prevalence of hepatitis C" ≥ 2% (Should Conduct hepatitis C test)
If the woman is HIV positive, then a hepatitis C test is required. Anti-HCV laboratory-based immunoassay is the preferred method for testing for Hep C infection in pregnancy; if immunoassay is not available, anti-HCV rapid diagnostic test (RDT) is recommended over dried blood spot (DBS) anti-HCV testing
If: Applicability: "HIV status" = "HIV positive" (Should Conduct hepatitis C test 2)
If the woman injects drugs, then a hepatitis C test is required. Anti-HCV laboratory-based immunoassay is the preferred method for testing for Hep C infection in pregnancy; if immunoassay is not available, anti-HCV rapid diagnostic test (RDT) is recommended over dried blood spot (DBS) anti-HCV testing.
If: Applicability: "Current alcohol and/or other substance use" = "Injectable drugs" (Should Conduct hepatitis C test 3)
If a woman is a sex worker, then a hepatitis C test is required. Anti-HCV laboratory-based immunoassay is the preferred method for testing for Hep C infection in pregnancy; if immunoassay is not available, anti-HCV rapid diagnostic test (RDT) is recommended over dried blood spot (DBS) anti-HCV testing.
If: Applicability: "Occupation" = "Informal employment (sex worker)" (Should Conduct hepatitis C test 4)